7. January 2010 02:43
Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA) announced today that
it has entered into two definitive agreements with AstraZeneca to settle
patent litigation regarding Teva’s U.S. generic versions of
AstraZeneca’s Prilosec® (omeprazole) and Nexium® (esomeprazole),
including all claims for patent infringement and damages.
Under the terms of the omeprazole agreement, Teva will obtain a release
for all past sales of its generic omeprazole and will continue to market
its product in the U.S. and will make a one-time payment to AstraZeneca.
As part of the esomeprazole agreement, AstraZeneca has granted Teva a
license, subject to regulatory approval, to enter the U.S. market with
its generic esomeprazole delayed-release capsules on May 27, 2014, or
earlier in certain circumstances. Additional details were not disclosed.
http://www.tevapharm.com/
News-Medical.Net provides this medical information service in accordance
with these
terms and conditions.
Please note that medical information found
on this website is designed to support, not to replace the relationship
between patient and physician/doctor and the medical advice they may provide.
Subscribe